Barings’s AbbVie ABBV Stock Holding History

Barings’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,298	Closed	-$297K	–	180
2025 Q4	$297K	Buy	1,298 +334	+35%	+$76.1K	0.01%	151
2025 Q3	$223K	Sell	964 -520	-35%	-$106K	﹤0.01%	163
2025 Q2	$275K	Buy	1,484 +47	+3%	+$8.73K	0.01%	159
2025 Q1	$301K	Sell	1,437 -191	-12%	-$37.1K	0.01%	152
2024 Q4	$289K	Buy	1,628 +589	+57%	+$108K	0.01%	152
2024 Q3	$205K	Buy	+1,039	New	+$194K	﹤0.01%	157
2023 Q3	–	Sell	-1,491	Closed	-$201K	–	150
2023 Q2	$201K	Buy	+1,491	New	+$219K	0.01%	162
2022 Q4	–	Sell	-2,719	Closed	-$365K	–	188
2022 Q3	$365K	Sell	2,719 -11,581	-81%	-$1.66M	0.01%	145
2022 Q2	$2.19M	Buy	14,300 +3,269	+30%	+$500K	0.08%	114
2022 Q1	$1.79M	Sell	11,031 -872	-7%	-$127K	0.05%	142
2021 Q4	$1.61M	Sell	11,903 -2,256	-16%	-$266K	0.04%	165
2021 Q3	$1.53M	Buy	14,159 +5,541	+64%	+$633K	0.03%	164
2021 Q2	$970K	Sell	8,618 -1,176	-12%	-$132K	0.02%	220
2021 Q1	$1.06M	Sell	9,794 -634	-6%	-$67.8K	0.03%	224
2020 Q4	$1.12M	Sell	10,428 -118,363	-92%	-$11.4M	0.03%	218
2020 Q3	$11.3M	Buy	128,791 +13,479	+12%	+$1.27M	0.26%	62
2020 Q2	$8.79M	Hold	115,312	–	–	0.29%	67
2020 Q1	$8.79M	Buy	115,312 +27	+0%	+$2.3K	0.29%	67
2019 Q4	$10.2M	Buy	115,285 +14,386	+14%	+$1.19M	0.27%	65
2019 Q3	$7.64M	Buy	100,899 +760	+0.8%	+$52.1K	0.17%	121
2019 Q2	$7.28M	Sell	100,139 -35,696	-26%	-$2.81M	0.16%	129
2019 Q1	$10.9M	Buy	135,835 +9,052	+7%	+$741K	0.25%	75
2018 Q4	$11.7M	Sell	126,783 -1,059	-0.8%	-$93.1K	0.21%	83
2018 Q3	$12.1M	Sell	127,842 -51,170	-29%	-$4.85M	0.17%	97
2018 Q2	$16.6M	Buy	179,012 +23,160	+15%	+$2.26M	0.24%	74
2018 Q1	$14.8M	Buy	155,852 +11,043	+8%	+$1.21M	0.21%	75
2017 Q4	$14M	Buy	144,809 +27,300	+23%	+$2.57M	0.18%	96
2017 Q3	$10.4M	Hold	117,509	–	–	0.19%	79
2017 Q2	$8.52M	Sell	117,509 -211,709	-64%	-$14.2M	0.25%	81
2017 Q1	$21.5M	Buy	329,218 +158,809	+93%	+$9.98M	0.24%	65
2016 Q4	$10.7M	Sell	170,409 -15,700	-8%	-$958K	0.27%	36
2016 Q3	$11.7M	Buy	186,109 +84,400	+83%	+$5.46M	0.3%	30
2016 Q2	$6.3M	Sell	101,709 -95,100	-48%	-$5.79M	0.16%	77
2016 Q1	$11.2M	Buy	196,809 +88,500	+82%	+$4.93M	0.3%	41
2015 Q4	$6.42M	Sell	108,309 -34,700	-24%	-$2M	0.16%	74
2015 Q3	$7.78M	Sell	143,009 -13,700	-9%	-$892K	0.19%	63
2015 Q2	$10.5M	Sell	156,709 -29,517	-16%	-$1.93M	0.32%	55
2015 Q1	$10.9M	Buy	186,226 +29,100	+19%	+$1.76M	0.25%	48
2014 Q4	$10.3M	Buy	157,126 +62,000	+65%	+$3.91M	0.23%	59
2014 Q3	$5.49M	Buy	95,126 +19,600	+26%	+$1.09M	0.12%	122
2014 Q2	$4.26M	Sell	75,526 -88,300	-54%	-$4.63M	0.13%	164
2014 Q1	$8.42M	Sell	163,826 -19,000	-10%	-$960K	0.26%	70
2013 Q4	$9.65M	Sell	182,826 -31,300	-15%	-$1.54M	0.4%	49
2013 Q3	$9.58M	Buy	214,126 +11,800	+6%	+$523K	0.41%	45
2013 Q2	$8.36M	Buy	+202,326	New	+$8.85M	0.38%	54

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barings's ABBV Position: Q1 2026 in Review

Barings sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,298 shares — an estimated $297K sold.

Barings first reported a position in ABBV in Q2 2013 and held it in 45 quarters. The position peaked at $21.5M in Q1 2017. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Barings reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Barings sold 1,298 AbbVie shares in Q1 2026, an estimated $297K.
Barings first reported a position in AbbVie in Q2 2013 and held it in 45 quarters.
Barings's AbbVie position peaked at $21.5M in Q1 2017.
4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Barings's 13F filing for Q1 2026, filed 6 May 2026.